@article{BaurRautenbergFaulstichetal.2014,
  author    = {Baur, Stefanie and Rautenberg, Maren and Faulstich, Manuela and Grau, Timo and Severin, Yannik and Unger, Clemens and Hoffmann, Wolfgang H. and Rudel, Thomas and Autenrieth, Ingo B. and Weidenmaier, Christopher},
  title     = {A Nasal Epithelial Receptor for Staphylococcus aureus WTA Governs Adhesion to Epithelial Cells and Modulates Nasal Colonization},
  series = {PLOS PATHOGENS},
  volume    = {10},
  journal   = {PLOS PATHOGENS},
  number    = {5},
  issn      = {1553-7374},
  doi       = {10.1371/journal.ppat.1004089},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-116280},
  pages     = {e1004089},
  year      = {2014},
  abstract  = {Nasal colonization is a major risk factor for S. aureus infections. The mechanisms responsible for colonization are still not well understood and involve several factors on the host and the bacterial side. One key factor is the cell wall teichoic acid (WTA) of S. aureus, which governs direct interactions with nasal epithelial surfaces. We report here the first receptor for the cell wall glycopolymer WTA on nasal epithelial cells. In several assay systems this type F-scavenger receptor, termed SREC-I, bound WTA in a charge dependent manner and mediated adhesion to nasal epithelial cells in vitro. The impact of WTA and SREC-I interaction on epithelial adhesion was especially pronounced under shear stress, which resembles the conditions found in the nasal cavity. Most importantly, we demonstrate here a key role of the WTA-receptor interaction in a cotton rat model of nasal colonization. When we inhibited WTA mediated adhesion with a SREC-I antibody, nasal colonization in the animal model was strongly reduced at the early onset of colonization. More importantly, colonization stayed low over an extended period of 6 days. Therefore we propose targeting of this glycopolymer-receptor interaction as a novel strategy to prevent or control S. aureus nasal colonization.},
  language  = {en}
}
@article{StanglHaasEichneretal.2020,
  author    = {Stangl, Stephanie and Haas, Kirsten and Eichner, Felizitas A. and Grau, Anna and Selig, Udo and Ludwig, Timo and Fehm, Tanja and St{\"u}bner, Tanja and Rashid, Asarnusch and Kerscher, Alexander and Bargou, Ralf and Hermann, Silke and Arndt, Volker and Meyer, Martin and Wildner, Manfred and Faller, Hermann and Schrauder, Michael G. and Weigel, Michael and Schlembach, Ulrich and Heuschmann, Peter U. and W{\"o}ckel, Achim},
  title     = {Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease — the "Breast cancer care for patients with metastatic disease" (BRE-4-MED) registry},
  series = {Pilot and Feasibility Studies},
  volume    = {6},
  journal   = {Pilot and Feasibility Studies},
  doi       = {10.1186/s40814-019-0541-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229149},
  year      = {2020},
  abstract  = {Background: Patients with metastatic breast cancer (MBC) are treated with a palliative approach with focus oncontrolling for disease symptoms and maintaining high quality of life. Information on individual needs of patients andtheir relatives as well as on treatment patterns in clinical routine care for this specific patient group are lacking or arenot routinely documented in established Cancer Registries. Thus, we developed a registry concept specifically adaptedfor these incurable patients comprising primary and secondary data as well as mobile-health (m-health) data. Methods: The concept for patient-centered "Breast cancer care for patients with metastatic disease"(BRE-4-MED)registry was developed and piloted exemplarily in the region of Main-Franconia, a mainly rural region in Germanycomprising about 1.3 M inhabitants. The registry concept includes data on diagnosis, therapy, progression, patient-reported outcome measures (PROMs), and needs of family members from several sources of information includingroutine data from established Cancer Registries in different federal states, treating physicians in hospital as well as inoutpatient settings, patients with metastatic breast cancer and their family members. Linkage with routine cancerregistry data was performed to collect secondary data on diagnosis, therapy, and progression. Paper and online-basedquestionnaires were used to assess PROMs. A dedicated mobile application software (APP) was developed to monitorneeds, progression, and therapy change of individual patients. Patient's acceptance and feasibility of data collection inclinical routine was assessed within a proof-of-concept study. Results: The concept for the BRE-4-MED registry was developed and piloted between September 2017 and May 2018.In total n= 31 patients were included in the pilot study, n= 22 patients were followed up after 1 month. Recordlinkage with the Cancer Registries of Bavaria and Baden-W{\"u}rttemberg demonstrated to be feasible. The voluntary APP/online questionnaire was used by n= 7 participants. The feasibility of the registry concept in clinical routine waspositively evaluated by the participating hospitals. Conclusion: The concept of the BRE-4-MED registry provides evidence that combinatorial evaluation of PROMs, needsof family members, and raising clinical parameters from primary and secondary data sources as well as m-healthapplications are feasible and accepted in an incurable cancer collective.},
  language  = {en}
}